Phase III study of cyclophosphamide, doxorubicin, and etoposide compared with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer

被引：18

作者：

De Jong, Wouter K. ^{[1
]}

Groen, Harry J. M. ^{[1
]}

Koolen, Mia G. J. ^{[2
]}

Biesma, Bonne ^{[3
]}

Willems, Luuk N. A. ^{[4
]}

Kwa, Hian-Bie ^{[5
]}

van Bochove, Aart ^{[6
]}

van Tinteren, Harm ^{[7
]}

Smit, Egbert F. ^{[8
]}

机构：

[1] Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[2] Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands

[3] Jeroen Bosch Hosp, Dept Pulmonol, sHertogenbosch, Netherlands

[4] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands

[5] Onze Lieve Vrouw Hosp, Dept Pulmonol, Amsterdam, Netherlands

[6] Zaans Med Ctr, Dept Med, Zaandam, Netherlands

[7] Ctr Comprehens Canc, Amsterdam, Netherlands

[8] Vrije Univ Amsterdam, Med Ctr, Dept Pulmonol, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2007年 / 43卷 / 16期

关键词：

small-cell lung cancer; chemotherapy; extensive disease; phase III study;

D O I：

10.1016/j.ejca.2007.07.029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The progression-free survival (PFS) of cyclophosphamide/doxorubicin/etoposide (CDE) and carboplatin/paclitaxel (CP) was compared in chemonaive patients with extensive disease small-cell lung cancer (ED-SCLC). A total of 203 patients were randomised to three-weekly CDE (n=102) or CP (n=101) for five cycles. Tumour response rates in CDE and CP were 60% and 61%. PFS of CP was 5.2 months, PFS of CDE 4.9 months (p=0.60). The major difference in toxicity between CDE and CP was grade 4 leukocytopaenia in 64% and 9% of the patients (p < 0.0001), leading to febrile neutropaenia in 30% and 4% of the patients (p < 0.0001), respectively This was the reason for differences in the total number of hospital admissions (63 for CDE and 40 for CP, p=0.0025). This study failed to demonstrate any benefit in PFS with CP compared with CDE. CP was associated with significantly less haematological toxicity, leading to 37% less hospital admissions for febrile neutropaenia. (c) 2007 Elsevier Ltd. All rights reserved.

引用

页码：2345 / 2350

页数：6

共 22 条

[1] EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours [J].

Aapro, M. S. ;

Cameron, D. A. ;

Pettengell, R. ;

Bohlius, J. ;

Crawford, J. ;

Ellis, M. ;

Kearney, N. ;

Lyman, G. H. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, D. C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (15) :2433-2453

[2] Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: A prospective European organization for research and treatment of cancer-lung cancer group phase III trial-08923 [J].

Ardizzoni, A ;

Tjan-Heijnen, VCG ;

Postmus, PE ;

Buchholz, E ;

Biesma, B ;

Karnicka-Mlodkowska, H ;

Dziadziuszko, R ;

Burghouts, J ;

van Meerbeeck, JP ;

Gans, S ;

Legrand, C ;

Debruyne, C ;

Giaccone, G ;

Manegold, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (19) :3947-3955

[3] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].

CALVERT, AH ;

NEWELL, DR ;

GUMBRELL, LA ;

OREILLY, S ;

BURNELL, M ;

BOXALL, FE ;

SIDDIK, ZH ;

JUDSON, IR ;

GORE, ME ;

WILTSHAW, E .

JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756

[4] Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: Perceptible progress [J].

Chute, JP ;

Chen, T ;

Feigal, E ;

Simon, R ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (06) :1794-1801

[5]

DEPPERMANN KM, 1999, P AN M AM SOC CLIN, V18, pA482

[6] Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer [J].

Eckardt, JR ;

von Pawel, J ;

Papai, Z ;

Tomova, A ;

Tzekova, V ;

Crofts, TE ;

Brannon, S ;

Wissel, P ;

Ross, G .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2044-2051

[7] MAINTENANCE CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER - LONG-TERM RESULTS OF A RANDOMIZED TRIAL [J].

GIACCONE, G ;

DALESIO, O ;

MCVIE, GJ ;

KIRKPATRICK, A ;

POSTMUS, PE ;

BURGHOUTS, JTM ;

BAKKER, W ;

KOOLEN, MGJ ;

VENDRIK, CPJ ;

ROOZENDAAL, KJ ;

PLANTING, AST ;

VANZANDWIJK, N ;

TENVELDE, GJM ;

SPLINTER, TAW .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1230-1240

[8] Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 study [J].

Gridelli, C ;

Manzione, L ;

Perrone, F ;

Veltri, E ;

Cioffi, R ;

Caprio, MG ;

Frontini, L ;

Rossi, A ;

Barletta, E ;

Barzelloni, ML ;

Bilancia, D ;

Gallo, C .

BRITISH JOURNAL OF CANCER, 2001, 84 (01) :38-41

[9] Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: A non-cross-resistant schedule [J].

Groen, HJM ;

Fokkema, E ;

Biesma, B ;

Kwa, B ;

van Putten, JWG ;

Postmus, PE ;

Smit, EF .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :927-932

[10] Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer [J].

Hanna, N ;

Bunn, PA ;

Langer, C ;

Einhorn, L ;

Guthrie, T ;

Beck, T ;

Ansar, R ;

Ellis, P ;

Byrne, M ;

Morrison, M ;

Hariharan, S ;

Wang, B ;

Sandler, A .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (13) :2038-2043

← 1 2 3 →